Ocular TherapeutixFRA:0OT -2.94%51 Days Payable is 416.18 as of Mar. 2026, which is 5% below its 10-year median of 439.90. GuruFocus rates FRA:0OT with a GF Score™ of 51/100 and a GF Value™ of €3.96 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 703 Biotechnology companies, Ocular Therapeutix ranks better than 71.83% on this metric.
The historical rank and industry rank for Ocular Therapeutix's Days Payable or its related term are showing as below:
FRA:0OT'
s Days Payable Range Over the Past 10 Years
Min: 231.25 Med: 439.9 Max: 2565.2
Current: 318.28
During the past 13 years, Ocular Therapeutix's highest Days Payable was 2565.20. The lowest was 231.25. And the median was 439.90.
FRA:0OT's Days Payable is ranked better than 71.83% of 703
companies
in the Biotechnology industry
Industry Median: 113.76
vs FRA:0OT: 318.28
Ocular Therapeutix's Days Payable
increased
from Mar. 2025 (322.93) to Mar. 2026 (416.18).
It may suggest that Ocular Therapeutixdelayed paying its suppliers.
Ocular Therapeutix Days Payable Related Terms
Ocular Therapeutix Days Payable Historical Data
* Premium members only.
The historical data trend for Ocular Therapeutix's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0OT vs NKTR, PVLA, GENB: Days Payable Comparison
For the Biotechnology subindustry, Ocular Therapeutix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocular Therapeutix Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Days Payable distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ocular Therapeutix's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix (FRA:0OT) has a Days Payable of 416.18 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ocular Therapeutix and its competitors. This is near median its historical median of 439.90. Over the past decade, Ocular Therapeutix's Days Payable has ranged from 231.25 to 2,565.20. According to the industry distribution chart, Ocular Therapeutix ranks #198 out of 703 companies in the Biotechnology industry, placing it in the top 28.2%.
Is Ocular Therapeutix's Days Payable too high?
Ocular Therapeutix's current Days Payable of 416.18 is near median its 10-year median of 439.90. Over the past 10 years, this metric has ranged from a low of 231.25 to a high of 2,565.20. The Biotechnology industry median Days Payable is 113.76. Ocular Therapeutix's value of 416.18 is 265.8% above this industry median. Based on the distribution chart, Ocular Therapeutix ranks #198 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Days Payable compare to NKTR and PVLA?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #198 out of 703 companies for Days Payable. This puts Ocular Therapeutix in the upper half of its industry. The industry median Days Payable is 113.76. Ocular Therapeutix's value of 416.18 is 265.8% above this benchmark. Historically, Ocular Therapeutix's own Days Payable has ranged from 231.25 to 2,565.20 over the past decade. While the company's 10-year median is 439.90 vs. the industry median of 113.76, Ocular Therapeutix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocular Therapeutix's current Days Payable of 416.18 is 265.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ocular Therapeutix and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocular Therapeutix's current Days Payable is 416.18, which is near median its own 10-year median of 439.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (FRA:0OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.96, compared to a current price of €8.25 — trading 108.3% above its estimated fair value. The current Days Payable is 416.18, which is near median its 10-year median of 439.90 and 265.8% above the Biotechnology industry median of 113.76. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ocular Therapeutix (FRA:0OT), the current Days Payable is 416.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?
Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued.
The current stock price of €8.25 is trading 108.3% above its estimated GF Value™ of €3.96.
GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.
Key valuation signals for FRA:0OT:
Days Payable: 416.18 (near median its 10-year median of 439.90)
GF Value™: €3.96 vs. price of €8.25 (108.3% above fair value)
Industry Position: 265.8% above the Biotechnology median (#198 of 703)
No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score
Get the complete analysis for FRA:0OT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0OT has been successfully added to your 
